Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein

Microscopy Research and Technique

Volumn 50, Issue 4, 2000, Pages 316-324

  Cole, Greg M ^a,c   Ard, March D ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

Author keywords

Apolipoprotein E; A ; Microglia

Indexed keywords

CEREBROSPINAL FLUID; GLYCOPROTEINS; NEURODEGENERATIVE DISEASES;

ALZHEIMER AMYLOID; ALZHEIMERS DISEASE; AMYLOID BETAS; AMYLOID Β-PROTEIN; APOLIPOPROTEIN E; HYDROPHOBIC PROTEIN; LIPOPROTEIN PARTICLES; LIPOPROTEIN RECEPTORS; MICROGLIA; SCAVENGER RECEPTOR;

LIPOPROTEINS;

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; CLUSTERIN; LIPOPROTEIN; LIPOPROTEIN RECEPTOR; SCAVENGER RECEPTOR;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; ENDOCYTOSIS; GLIA; HISTOPATHOLOGY; LYSOSOME; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SENILE PLAQUE;

EID: 0034663037     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0029(20000815)50:4<316::AID-JEMT11>3.0.CO;2-E     Document Type: Review

References (111)

1. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. 1996. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271:518-520.
2. Aleshkov S, Abraham CR, Zannis VI. 1997. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Biochemistry 36:10571-10580.
3. Ard MD, Cole GM, Wei J, Mehrle AP, Fratkin JD. 1996. Scavenging of Alzheimer's amyloid β-protein by microglia in culture. J Neurosci Res 43:190-202.
4. Bales KR, Verina T, Ghetti B, Dodel RC, Du Y, Altstie L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Paul SM. 1997. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nature Genet 17: 263-264.
5. Beffert U, Aumont N, Dea D, Lussier-Cacan S, Davignon J, Poirier J. 1998. β-Amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons. J Neurochem 70:1458-1466.
6. Bell MD, Lopez-Gonzalez R, Lawson L, Hughes D, Fraser I, Gordon S, Perry VH. 1994. Upregulation of the macrophage scavenger receptor in response to different forms of injury in the CNS. J Neurocytol 23:605-613.
7. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ. 1996. Amyloid β-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271:32916-32922.
8. Bodovitz S, Klein WL. 1996. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271:4436-4440.
9. Boland K, Manias K, Perlmutter DH. 1995. Specificity in recognition of amyloid-β peptide by the serpin-enzyme complex receptor in hepatoma cells and neuronal cells. J Biol Chem 47:28022-28028.
10. Borghini I, Barja F, Pometta D, James RW. 1995. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta 1255:192-200.
11. Carter DB, Dunn E, Mckinley DD, Boyle TP, Kuiper SL, Weaver RJ, Vidmar TJ, Boller JA, Lennon DJ, Stratman NC, Gurney ME. 1999. Increased levels of apolipoprotein E4 accelerate amyloid deposition in APPsw transgenic mouse brain. Soc Neurosci Abstr 25: 1348.
12. Castano EM, Prelli F, Pras M, Frangione B. 1995a. Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L. J Biol Chem 270: 17610-17615.
13. Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B. 1995b. Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E. Biochem J 306: 599-604.
14. Chan W, Fornwald J, Brawner M, Wetzel, R. 1996. Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide A beta. Biochemistry 35:7123-7130.
15. Christie RH, Freeman M, Hyman BT. 1996. Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. Am J Pathol 148:399-403.
16. Chu T, Tran T, Yang F, Beech W, Cole GM, Frautschy SA. 1998. Effect of chloroquine and leupeptin on intracellular accumulatin of amyloid-beta (A beta) 1-42 peptide in a murine N9 microglial cell line. FEBS Lett 436:439-444.
17. Chu TS, Frautschy SA, Yang F, Teter B, Chen P, Beech W, Sigel JJ, Howard BD, Cole GM. 1997. Lipoprotein-dependent Aβ clearance in vivo and in vitro. Soc Neurosci Abstr 23: 1638.
18. Chung H, Brazil MI, Soe TT, Maxfield FR. 1999. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid β-peptide by microglial cells. 1999. J Biol Chem 274:32301-32308.
19. Cole GM, Beech W, Frautschy SA, Sigel J, Glasgow C, Ard MD. 1999. Lipoprotein effects on Aβ accumulation and degradation by microglia in vitro. J Neurosci Res 57: 504-520.
20. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1994. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet 7: 180-183.
21. Corrigan FM, Horrobin DF, Skinner ER, Besson JA, Cooper MB. 1998. Abnormal content of n-6 and n-3 long-chain fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. Int J Biochem Cell Biol 30: 197-207.
22. Deng J, Rudick V, Dory L. 1995. Lysosomal degradation and sorting of apolipoprotein E in macrophages. J Lipid Res 36:2129-2140.
23. Dickson DW. 1997. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 56:321-339.
24. Dickson DW, Lee SC, Mattiace LA, Yen SC, Brosnan C. 1993. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7:75-83.
25. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. 1996. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 382:716-719.
26. Enya M, Morishima-Kawashima M, Shinkai Y, Kusui K, Khan K, Games D, Schenk D, Sugihara S, Yamaguchi H, Ihara Y. 1999. Appearance of sodium dodecyl sulfate-stable amyloid β-protein (Aβ) dimer in the cortex during aging. Am J Pathol 154:271-279.
27. Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT. 1995. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implicatioins for the pathogenesis and treatment of alzheimer disease. Proc Natl Acad Sci USA 92:763-767.
28. Fagan AM, Younkin LH, Morris JC, Phillips K, Younkin SG, Holtzman DM. 1999. Lipoprotein profiles of normal human cerebrospinal fluid of known APOE genotype. Soc Neurosci Abstr 25:1348.
29. Farhangrazi ZS, Ying H, Bu G, Dugan LL, Fagan AM, Choi DW, Holtzman DM. 1997. High density lipoprotein decreases β-amyloid toxicity in cortical cell culture. Neuroreport 8:1127-1130.
30. Frackowiak J, Wisniewski HM, Wegiel J, Merz GS, Iqbal K, Wang KC. 1992. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol (Berl) 84:225-233.
31. Frautschy SA, Cole GM, Baird A. 1992. Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am J Pathol 140:1389-1399.
32. Gearing M, Mori H, Mirra SS. 1996. Aβ-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 39:395-399.
33. Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak CS, Fenstennacher JD. 1996. Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 93:2312-2316.
34. Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T, Frangione B. 1993. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 293: 27-30.
35. Golabek A, Marques MA, Lalowski M, and Wisniewski T. 1995. Amyloid binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett 191:79-82.
36. Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, Brewer HB. 1986. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 78:815-821.
37. Hammad SM, Ranganathan S, Loukinova E, Twal WO, Argraves WS. 1997. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. J Biol Chem 272:18644-18649.
38. Hayek T, Oiknine J, Brook JG, Aviram M. 1994. Role of HDL apolipoprotein E in cellular cholesterol efflux: studies in apo E knockout transgenic mice. Biochem Biophys Res Commun 205:1072-1078.
39. Hollenbach E, Ackerman S, Hyman BT, Rebeck GW. 1998. Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer's disease. Neurology 50:1905-1907.
40. Holtzman DM, Bales RK, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM. 1999. Expression of human apolipoprotein E reduces amyloid-B deposition in a mouse model of Alzheimer's disease. J Clin Invest 103:R15-R21.
41. Honda M, Akiyama H, Yamada Y, Kondo H, Kawabe Y, Takeya M, Takahashi K, Suzuki H, Doi T, Sakamoto A, Ookawara S, Mato M, Gough PJ, Greaves DR, Gordon S, Kodama T, Matsushita M. 1998. Immunohistochemical evidence for a macrophage scavenger receptor in Mato cells and reactive microglia of ischemia and Alzheimer's disease. Biochem Biophys Res Commun 245:734-740.
42. Hyman B. 1997. Apolipoprotein E: Clinical, pathological, and biochemical correlations in Alzheimer's disease. In: Yankner BA and Roses AD, editors. Molecular mechanisms in Alzheimer's disease. Keystone Symposia on Molecular and Cellular Biology, Tamarron, Colorado, p. 5.
43. Hyman BT, Marzloff K, Arriagada PV. 1993. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol 52:594-600.
44. Ishii K, Tamaoka A, Mizusawa H, Shoji S, Ohtake T, Fraser PE, Takahashi H, Tsuji S, Gearing M, Mizutani T, Yamada S, Kato M, St. George-Hyslop PH, Mirra SS, Mori H. 1997. Aβ1-40 but not Aβ1-42 levels in cortex correlate with apolipoprotein E E4 allele dosage in sporadic Alzheimer's disease. Brain Res 748: 250-252.
45. Iwata N, Tsubuki S, Takaki Y, Watanabe, K., Sekiguchi M, Hosoki E, Watanabe K, Morishima-Kawashima M, Lee HJ , Hama, E., Sekine-Aizawa, Y., Saido TC. 2000. Identification of the major Aβ1-42 degrading catabolic pathway in brain parenychyma: Suppression leads to biochemical and pathological deposition. Nature Med 6:143-150.
46. Jordan J, Galindo MF, Miller RJ, Reardon CA, Getz GS, LaDu MJ. 1998. Isoform-specific effect of apolipoprotein E on cell survival and β-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci 18:195-204.
47. Kalaria RN. 1999. Microglia and Alzheimer's disease. Curr Opin Hematol 6:15-24.
48. Koudinov AR, Koudinova NV. 1997. Alzheimer's soluble amyloid beta protein is secreted by HepG2 cells as an apolipoprotein. Cell Biol Int 21:265-271.
49. Koudinov A, Matsubara E, Frangione B, Ghiso J. 1994. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 205:1164-1171.
50. Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J. 1996. Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: Association with high density lipoproteins. Biochem Biophys Res Commun 223:592-597.
51. Koudinov AR, Berezov TT, Kumar A, Koudinova NV. 1998. Alzheimer's amyloid β interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin Chim Acta 270:75-84.
52. Koudinova NV, Berezov TT, Koudinov AR. 1996. Multiple inhibitory effects of Alzheimer's peptide Abeta1-40 on lipid biosynthesis in cultured human HepG2 cells. FEBS Lett 393:204-206.
53. Kruth HS, Scarlatos HI, Lilly K, Chang J, Ifrim I. 1995. Sequestration of acetylated LDL and cholesterol crystals by human monocyte-derived macrophages. J Cell Biol 129:133-145.
54. Kuo Y-M, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE. 1996. Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271:4077-4081.
55. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. 1994. Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem 269:23403-23406.
56. LaDu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT. 1995. Purification of Apolipoprotein E attenuates isoform-specific binding to β-amyloid. J Biol Chem 270:9039-9042.
57. LaDu MJ, Gilligan SM, Lukens JR, Cabana VG, Reardon CA, Van Eldik LJ, Holtzman DM. 1998. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem 70:2070-2081.
58. 2 by amyloid β-peptides in vitro. Biochemistry 35: 9407-9414.
59. Lim GP, Russell MJ, Cullen MJ, Tokes ZA. 1997. Matrix metalloproteinases in dog brains exhibiting Alzheimer-like characteristics. J Neurochem 68:1606-1611.
60. Liu Y, Peterson DA, Schubert D. 1998. Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci USA 95:13266-13271.
61. Lucas M, Mazzone T. 1996. Cell surface proteoglycans modulate net synthesis and secretion of macrophage apolipoprotein E. J Biol Chems 271:13454-13459
62. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372: 92-94.
63. Mahley RW. 1996. Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Isr J Med Sci 32:414-29.
64. Mahley RW. 1997. Apolipoprotein E: Structure, function, and possible roles in neurodegenerative disease. In: Yankner B, Roses AD, editors. Molecular mechanisms in Alzheimer's disease. Keystone Symposia on Molecular and Cellular Biology, Tamarron, Colorado, p. 5.
65. Mahley RW, Nathan BP, Pitas RE. 1996. Apolipoprotein E. Structure, function, and possible roles in Alzheimer's disease. Ann NY Acad Sci 777:139-145.
66. Mann DMA, Iwatsubo T, Pickering-Brown SM, Owen F, Saido TC, Perry RH. 1997. Preferential deposition of amyloid β protein (Aβ) in the form of Aβ40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci Lett 221: 81-84.
67. Matsubara E, Soto C, Governale S, Frangione B, Ghiso J. 1996. Apolipoprotein J and Alzheimer's amyloid β solubility. Biochem J 316:671-679.
68. Mattiace LA, Davies P, Dickson DW. 1990. Detection of HLA-DR on microglia in the human brain is a function of both clinical and technical factors. Am J Pathol 136:1101-1114.
69. Mattson MP, Partin J, Begley JG. 1998. Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res 807: 167-76.
70. Mazzone T, Reardon C. 1994. Expression of heterologous human apolipoprotein E by J774 macrophages enhances cholesterol efflux to HDL3. J Lipid Res 35:1345-1353.
71. McDonald DR, Brunden KR, Landreth GE. 1997. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci 17:2284-2294.
72. McDonald DR, Bamberger ME, Combs CK, Landreth GE. 1998. β-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J Neurosci 18:4451-4460.
73. Nakamura S, Tamaoka A, Sawamura N, Kiatipattanasakul W, Nakayama H, Shoji S, Yoshikawa Y, Doi K. 1997. Deposition of amyloid beta protein (Aβ) subtypes [Aβ40 and Aβ42(43)] in canine senile plaques and cerebral amyloid angiopathy. Acta Neuropathol (Berl) 94: 323-328.
74. Namba Y, Tsuchiya H, Ikeda K. 1992. Apolipoprotein B immunoreactivity in senile plaque and vascular amyloids and neurofibrillary tangles in the brains of patients with alzheimer's disease. Neurosci Lett 134:264-266.
75. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. 2000. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283:1571-1577.
76. Nicoll JA, Roberts GW, Graham DI. 1995. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med 1:135-137.
77. Nishiyama E, Iwamoto N, Ohwada J, Arai H. 1997. Distribution of apolipoprotein E in senile plaques in brains with alzheimer's disease: investigation with the confocal laser scan microscope. Brain Res 750:20-24.
78. Paresce DM, Ghosh RN, Maxfield FR. 1996. Microglial cells internalize aggregates of the Alzheimer's disease amyloid β-protein via a scavenger receptor. Neuron 17:553-565.
79. Paresce DM, Chung H, Maxfield FR. 1997. Slow degradation of aggregates of the Alzheimer's disease amyloid β-protein by microglial cells. J Biol Chem 46:29390-29397.
80. Permanne B, Perez C, Soto C, Frangione B, Wisniewski T. 1997. Detection of apolipoprotein E dimeric soluble amyloid β complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 240:715-720.
81. Permanne B, Ji Y, Holtzman D, Frangione B, Wisniewski T. 1999. Aβ40 and Aβ42 clearance in a transgenic mouse model expressing human ApoE3 and ApoE4. Soc Neurosci Abstr 25:1058.
82. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. 1987. Lipoproteins and their receptors in the central nervous system. J Biol Chem 262:14352-14360.
83. 2 -macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol 37:211-217.
84. Rebeck GW, Alonzo NC, Berezovska O, Harr SD, Knowles RB, Growdon JH, Hyman BT, Mendez AJ. 1998. Structure and functions of human cerebrospinal fluid lipoproteins from individuals of different APOE genotypes. Exp Neurol 149:175-182.
85. Russo C, Angelini G, Dapino D, Piccini A, Piombo G, Schettini G, Chen S, Teller JK, Zaccheo D, Gambetti M, Tabaton M. 1998. Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proc Natl Acad Sci 95: 15598-15602.
86. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, Strittmatter WJ. 1994. Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 94: 860-869.
87. Saunders AM, Schmader K, Breitner JCS, Benson MD, Brown WT, Goldfarb L, Goldgaber D, Manwaring MG, Szymanski MH, McCown N, Dole KC, Schmechel DE, Strittmatter WJ, Pericak-Vance MA, Roses AD. 1993. Apolipoprotein E E4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 342:710-711.
88. Savage MJ, Trusko SP, Howland, DS, Pinsker LR, Mistretta S, Reaume AG, Greenberg BD, Siman R, Scott RW. 1998. Turnover of amyloid β-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 18:1743-1752.
89. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. 1999. Immunization with amyloid β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
90. Schmechel DE, Saunders AM, Strittmatter WJ, Crain B, Hulette C, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. 1993. Increased amyloid β-peptide deposition as a consequence of apolipoprotein E genotype in late-onset Alzheimers disease. Proc Natl Acad Sci USA 90:9649-9653.
91. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, Zagorski MG, Talafous J, Eisenberg M, Saunders AM, Roses AD, Goldgaber D. 1994. Transthyretin sequesters amyloid β protein and prevents amyloid formation. Proc Natl Acad Sci USA 91:8368-8372.
92. Shaffer LM, Dority MD, Gupta-Bansal R, Frederickson RCA, Younkin SG, Brunden KR. 1995. Amyloid β protein (Aβ) removal by neuroglial cells in culture. Neurobiol Aging 16:737-745.
93. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. 1998. Cholesterol depletion inhibits the generation of β-amyloid in neurons. Proc Natl Acad Sci USA 95:6460-6464.
94. Solomon B, Koppel R, Hanan E, Katzav T. 1996. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 93:452-455.
95. Strittmatter WJ, Weisgraber KH, Huang DY, Dong L-M, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. 1993. Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:8098-8102.
96. Styren SD, Civin WH, Rogers J. 1990. Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. Exp Neurol 110:93-104.
97. Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P. 1994. Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun 200:1598-1603.
98. Tooyama I, Kimura H, Akiyama H, McGeer PL. 1990. Reactive microglia express class I and class II major histocompatibility antigens in Alzheimer disease. Brain Res 523:273-280.
99. Urmoneit B, Prikulis I, Wihl G, D'Urso D, Frank R, Heeren J, Beisiegel U, Prior R. 1997. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab Invest 77:157-166.
100. Wang J, Dickson DW, Trojanowski JQ, Lee VM. 1999. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158:328-337.
101. Weisgraber KH, Mahley RW. 1996. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 10:1485-1494.
102. Wisniewski T, Castaño EM, Golabek A, Vogel T, Frangione B. 1994. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145:1030-1035.
103. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. 1993. Apolipoprotein E: binding to soluble Alzheimer's β-amyloid. Biochem Biophys Res Commun 192:359-365.
104. Wood SJ, Chan W, Wetzel R. 1996. Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 35:12623-12628.
105. Yamada Y, Doi T, Hamakubo T, Kodama T. 1998. Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cell Mol Life Sci 54:628-640.
106. Yan SD, Chen X, Fu J, Chen M, Zu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. 1996. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382:685-691.
107. Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG. 1998. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Aβ1-42 pathogenesis. J Neurosci Res 52:691-698.
108. Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN. 1997. Characterization of the binding of amyloid β peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem 68:721-725.
109. Yates SL, Embury PB, Angle JM, Brunden KR. 1999. A comparison of amyloid peptide-induced cytokine and chemokine synthesis. Soc Neurosci Abstr 25:1105.
110. Zhou Z, Smith JD, Greengard P, Gandy S. 1996. Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E. Mol Med 2:175-180.
111. Zlokovic BV, Martel CL, Mackic JB, Matsubara E, Wisniewski T, McComb JG, Frangione B, Ghiso J. 1994. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta. Biochem Biophys Res Commun 205:1431-1437.